|Safety, activity, and immune correlates of anti–PD-1 antibody in cancer|
SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ...
New England Journal of Medicine 366 (26), 2443-2454, 2012
|PD-1 blockade in tumors with mismatch-repair deficiency|
DT Le, JN Uram, H Wang, BR Bartlett, H Kemberling, AD Eyring, ...
New England Journal of Medicine 372 (26), 2509-2520, 2015
|Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates|
JR Brahmer, CG Drake, I Wollner, JD Powderly, J Picus, WH Sharfman, ...
Journal of clinical oncology 28 (19), 3167, 2010
|Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade|
DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ...
Science 357 (6349), 409-413, 2017
|Elucidation of a universal size-control mechanism in Drosophila and mammals|
J Dong, G Feldmann, J Huang, S Wu, N Zhang, SA Comerford, ...
Cell 130 (6), 1120-1133, 2007
|Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape|
JM Taube, RA Anders, GD Young, H Xu, R Sharma, TL McMiller, S Chen, ...
Science translational medicine 4 (127), 127ra37-127ra37, 2012
|Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti–PD-1 therapy|
JM Taube, A Klein, JR Brahmer, H Xu, X Pan, JH Kim, L Chen, DM Pardoll, ...
Clinical cancer research 20 (19), 5064-5074, 2014
|Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy|
SL Topalian, JM Taube, RA Anders, DM Pardoll
Nature Reviews Cancer 16 (5), 275-287, 2016
|Fulminant myocarditis with combination immune checkpoint blockade|
DB Johnson, JM Balko, ML Compton, S Chalkias, J Gorham, Y Xu, ...
New England Journal of Medicine 375 (18), 1749-1755, 2016
|The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints|
NJ Llosa, M Cruise, A Tam, EC Wicks, EM Hechenbleikner, JM Taube, ...
Cancer discovery 5 (1), 43-51, 2015
|Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAP|
Y Liu-Chittenden, B Huang, JS Shim, Q Chen, SJ Lee, RA Anders, JO Liu, ...
Genes & development 26 (12), 1300-1305, 2012
|The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals|
N Zhang, H Bai, KK David, J Dong, Y Zheng, J Cai, M Giovannini, P Liu, ...
Developmental cell 19 (1), 27-38, 2010
|Expression of Yes-associated protein in common solid tumors|
AA Steinhardt, MF Gayyed, AP Klein, J Dong, A Maitra, D Pan, ...
Human pathology 39 (11), 1582-1589, 2008
|Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody|
EJ Lipson, WH Sharfman, CG Drake, I Wollner, JM Taube, RA Anders, ...
Clinical Cancer Research 19 (2), 462-468, 2013
|Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas|
Y Jiao, TM Pawlik, RA Anders, FM Selaru, MM Streppel, DJ Lucas, ...
Nature genetics 45 (12), 1470-1473, 2013
|A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung cancer|
DL Rimm, G Han, JM Taube, SY Eunhee, JA Bridge, DB Flieder, R Homer, ...
JAMA oncology 3 (8), 1051-1058, 2017
|LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems|
JF Grosso, CC Kelleher, TJ Harris, CH Maris, EL Hipkiss, A De Marzo, ...
The Journal of clinical investigation 117 (11), 3383-3392, 2007
|Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma|
M Li, H Zhao, X Zhang, LD Wood, RA Anders, MA Choti, TM Pawlik, ...
Nature genetics 43 (9), 828-829, 2011
|Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation|
ER Lutz, AA Wu, E Bigelow, R Sharma, G Mo, K Soares, S Solt, A Dorman, ...
Cancer immunology research 2 (7), 616-631, 2014
|PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus, and overall survival|
EJ Lipson, JG Vincent, M Loyo, LT Kagohara, BS Luber, H Wang, H Xu, ...
Cancer immunology research 1 (1), 54-63, 2013